belzutifan

belzutifan Merck Receives Priority Review From FDA for New Drug Application for HIF-2α Inhibitor Belzutifan (MK-6482) KENILWORTH, N.J.–(BUSINESS WIRE) March 16, 2021 — Merck (NYSE: MRK), known as MSD outside the United States and Canada,